ACOLOGIX REPORTS RESULTS IN STUDY OF AC-100

Acologix has announced today that a Phase II clinical trial of AC-100 (Dentonin), a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells, met its primary goal of stimulating the formation of new dentin (the hard tissue of teeth that protects the tooth pulp and supports the outer enamel) when applied directly to tooth defects (prepared cavities). AC-100 also demonstrated a favorable safety profile.

The randomized, double-blind, placebo-controlled trial enrolled 35 patients who were candidates for at least two third-molar (wisdom teeth) extractions. Patients served as their own controls, with one molar treated with 200 micrograms AC-100 (applied on Days 0, 2 and 4 through the dentin tubules) and the other with a placebo. After two months, the teeth were extracted and evaluated for remaining dentin thickness, new dentin formation, inflammation and necrosis.